CCGs facing 'significant financial risk' after generic drug price surge
Clinical commissioning groups are facing “significant financial risk” this financial year due to supply issues pushing up the prices they have to pay for generic drugs.
You need to be an HSJ subscriber to read more
Subscribe to read the full article
With an HSJ subscription you’ll get access to:
- Expert Briefing newsletters, covering nine topics and regions
- Weekly Catch Up – a summary of the week’s most important stories
- Unlimited access to hsj.co.uk
- The HSJ app
Enquire about multi-user access